NCT00932529View on ClinicalTrials.gov

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

PHASE4CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Psychotic Disorders
Interventions
DRUG

Olanzapine

Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion

DRUG

Quetiapine

Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.

DRUG

Risperidone

Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.

DRUG

Ziprasidone

Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion

Trial Locations (1)

N-5035

Haukeland University Hospital, Division of Psychiatry, Bergen

All Listed Sponsors
lead

University of Bergen

OTHER

NCT00932529 - Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting | Biotech Hunter | Biotech Hunter